Anti-BMPR1B antibodies and methods of use

Patent metadata

Field	Value
Publication number	US-10934359-B2
Application number	US-201716095057-A
Country	US
Kind code	B2
Filing date	Apr 21, 2017
Priority date	Apr 21, 2016
Publication date	Mar 2, 2021
Grant date	Mar 2, 2021

Abstract

Provided are novel anti-BMPR1B antibodies and antibody drug conjugates, and methods of using such anti-BMPR1B antibodies and antibody drug conjugates to treat cancer.

First claim

The invention claimed is:

1. An isolated antibody that binds to BMPR1B and comprises:
(a) a light chain variable region (VL) set forth as SEQ ID NO: 21 and a heavy chain variable region (VH) set forth as SEQ ID NO: 23; or
(b) a VL set forth as SEQ ID NO: 41 and a VH set forth as SEQ ID NO: 43.

2. The isolated antibody of claim 1 , wherein the antibody is conjugated to a payload.

3. A nucleic acid encoding all or part of the antibody of claim 1 .

4. A vector comprising the nucleic acid of claim 3 .

5. A host cell comprising the nucleic acid of claim 3 .

6. The antibody of claim 1 , wherein:
(a) the antibody comprises residues 24-34 of SEQ ID NO: 21 for CDR-L1, residues 50-56 of SEQ ID NO: 21 for CDR-L2, residues 89-97 of SEQ ID NO: 21 for CDR-L3, residues 31-35 of SEQ ID NO: 23 for CDR-H1, residues 50-65 of SEQ ID NO: 23 for CDR-H2, and residues 95-102 of SEQ ID NO: 23 for CDR-H3, wherein the residues are numbered according to Kabat; or
(b) the antibody comprises residues 24-34 of SEQ ID NO: 41 for CDR-L1, residues 50-56 of SEQ ID NO: 41 for CDR-L2, residues 89-97 of SEQ ID NO: 41 for CDR-L3, residues 31-35 of SEQ ID NO: 43 for CDR-H1, residues 50-65 of SEQ ID NO: 43 for CDR-H2, and residues 95-102 of SEQ ID NO: 43 for CDR-H3, wherein the residues are numbered according to Kabat.

7. The antibody of claim 1 , wherein the antibody comprises a light chain variable region set forth as SEQ ID NO: 21 and a heavy chain variable region set forth as SEQ ID NO: 23.

8. The antibody of claim 1 , wherein the antibody comprises a light chain variable region set forth as SEQ ID NO: 41 and a heavy chain variable region set forth as SEQ ID NO: 43.

9. The antibody of claim 1 , wherein the antibody is a chimeric, CDR grafted, humanized, or human antibody, or an immunoreactive fragment thereof.

Assignees

• Abbvie Stemcentrx Llc

Inventors

• Roy Somdutta
• Saunders Laura
• Franklin Casey
• Martinez Kevin
• Fong Sarah
• Huang Zhao
• Juarez Silvia
• He Alina
• Loving Kathryn A
• Vivona Sandro

Classifications

• A61K47/68035

  the drug being a pyrrolobenzodiazepine · CPC title

• A61K47/6803

  Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates · CPC title

• C07K2317/77

  Internalization into the cell · CPC title

• C07K2317/33

  Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title